secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024723
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q3 net loss widens to $41.9M; paltusotine Phase 3 on track for Q3 2023 topline
--------------------------------------------------------------------------------

- Net loss $41.9M in Q3 2022 vs $27.9M in Q3 2021; R&D spend rose to $32.0M from $21.6M.
- Cash and investments $368.4M as of Sep 30, 2022, up from $333.7M at Dec 31, 2021.
- Phase 3 PATHFNDR-1 for paltusotine in acromegaly fully enrolled; topline data expected Q3 2023.
- Long-term extension data: paltusotine maintained IGF-1 comparable to injected SRLs for up to 103 weeks; 89% preferred paltusotine.
- Appointed Dana Pizzuti, M.D. as chief development officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/0000950170-22-024723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/crnx-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer